Abstract: An assembly is provided that includes an inner support, an intermediate support, an outer support, first and second pins and a pin actuator. The intermediate support circumscribes and rotatably attaches to the inner support about a first axis. The outer support includes a first flange and a second flange. The intermediate support is laterally between the first flange and the second flange. The first and the second pins rotatably attach the intermediate support to the outer support about a second axis. The first pin is arranged with the first flange, and the second pin is arranged with the second flange. The pin actuator includes a drive element projecting laterally through the outer support. The pin actuator is configured to translate the second pin along the second axis upon rotation of the drive element about a rotational axis thereof.

Abstract: An assembly is provided that includes an inner support, an intermediate support, an outer support, first and second pins and a pin actuator. The intermediate support circumscribes and rotatably attachs to the inner support about a first axis. The outer support includes a first flange and a second flange. The intermediate support is laterally between the first flange and the second flange. The first and the second pins rotatably attach the intermediate support to the outer support about a second axis. The first pin is arranged with the first flange, and the second pin is arranged with the second flange. The pin actuator includes a drive element projecting laterally through the outer support. The pin actuator is configured to translate the second pin along the second axis upon rotation of the drive element about a rotational axis thereof.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Abstract: A system includes a computing device that includes a memory configured to store instructions. The computing device also includes a processor to execute the instructions to perform operations that include receiving a request from an imaging device indicating that the imaging device is unable to present textual content of an asset. The request includes one or more attributes of the textual content of the asset and the request is sent from the imaging device absent user input. Operations also include identifying an appropriate amount of font information from the received one or more attributes for the imaging device to present the asset, and, providing the identified font information to the imaging device for presenting the asset.

Abstract: A method of determining the activation energy Ea for degradation of a chemical species includes in sequence the steps of a) simultaneously incubating a plurality of samples of the chemical species in a single unitary device at a plurality of constant temperatures T, in each case for an incubation time t selected to result in loss of at most 20 mol % of the amount originally present; b) quenching each of the samples to stop degradation; c) determining the mole fraction m of the chemical species remaining in each of the quenched samples, relative to the amount present before incubating; d) determining for each sample a reaction rate coefficient kobs according to the equation k obs ? ( T ) = 1 - m ? ( T ) t ; and e) performing numerical regression of the kobs values obtained in step d) and the corresponding temperatures T in ° K to derive the activation energy Ea according to the following equation k obs = k 0 ? exp ? ( E a R ? ( 1 T - 1 T 0 ) ) , or t

Abstract: A method of determining the activation energy Ea for degradation of a chemical species includes in sequence the steps of a) simultaneously incubating a plurality of samples of the chemical species in a single unitary device at a plurality of constant temperatures T, in each case for an incubation time t selected to result in loss of at most 20 mol % of the amount originally present; b) quenching each of the samples to stop degradation; c) determining the mole fraction m of the chemical species remaining in each of the quenched samples, relative to the amount present before incubating; d) determining for each sample a reaction rate coefficient kobs according to the equation k obs ? ( T ) = 1 - m ? ( T ) t ; and e) performing numerical regression of the kobs values obtained in step d) and the corresponding temperatures T in ° K to derive the activation energy Ea according to the following equation k obs = k 0 ? exp ? ( E a R ? ( 1 T - 1 T 0 ) ) , or to

Abstract: A system includes a computing device that includes a memory configured to store instructions. The computing device also includes a processor to execute the instructions to perform operations that include receiving a request from an imaging device indicating that the imaging device is unable to present textual content of an asset. The request includes one or more attributes of the textual content of the asset and the request is sent from the imaging device absent user input. Operations also include identifying an appropriate amount of font information from the received one or more attributes for the imaging device to present the asset, and, providing the identified font information to the imaging device for presenting the asset.

Abstract: A system includes a first computing device that includes a memory configured to store instructions. The first computing device also includes a processor to execute the instructions to perform a method that includes receiving one or more environment characteristics of a communication connection between a user device and a font provider. The method also includes determining an appropriate amount of font information of a web asset to provide to the user device based upon the one or more environment characteristics, and, providing the appropriate amount of font information of the web asset to the user device for presenting the web asset.

Abstract: A system includes a first computing device that includes a memory configured to store instructions. The first computing device also includes a processor to execute the instructions to perform a method that includes receiving, at a font service provider, a request from a second computing device for one or more fonts. The method also includes authenticating the user of the second computing device from the received request, and, providing access to data representative of the one or more fonts identified in the received request for use by the second computing device. The data representative of the one or more fonts resides in a predefined portion of memory assigned to the user of the second computing device.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also provides methods of classifying and treating patients based on prognosis. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the diagnostic, prognostic and statistical methods disclosed herein.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also provides methods of classifying and treating patients based on prognosis. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the diagnostic, prognostic and statistical methods disclosed herein.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Abstract: The present invention relates to methods for identifying one or more reporter genes for a particular biological pathway of interest. The reporter genes of this invention are particularly useful for analyzing the activity of particular biological pathways of interest, and may be further used in the design of drugs, drug therapies or other biological agents (e.g., insecticides, herbicides, fungicides, antibiotics, or antivirals) to target a particular biological pathway. The present invention also relates to methods for identifying one or more target genes for a particular biological pathway of interest. Target genes of the invention are useful as specific targets for drugs which may be designed to enhance, inhibit, or modulate a particular biological pathway. Methods to identify genes which modify the function or structure of a member (e.g., compound or gene product) of a particular biological pathway are provided.

Abstract: A piston for a low pressure fluid accumulator of a hydraulic control unit of a vehicle brake system includes a cylindrical body having an outer surface defining a first end surface of the piston. The first end surface includes a plurality of interconnected ridges. The ridges have outer surfaces and form cavities therebetween. Each ridge is adapted to provide a sealing surface between the first end surface of the piston and an inner surface of a fluid accumulator in which the piston may be inserted. In one embodiment of the invention, the closed end of the piston includes a thick self-supporting wall. A thin skirt extends from the thick self-supporting wall toward the open end of the piston. A plurality of axially extending skirt support ribs is formed on the inner surface of the piston skirt.

Abstract: The present invention relates to genes in Saccharomyces cerevisiae which are essential for germination and proliferation of S. cerevisiae and using the identified genes or their encoded proteins as targets for highly specific antifungal agents, insecticides, herbicides and anti-proliferation drugs. The present invention provides antisense molecules and ribozymes comprising sequences complementary to the sequences of mRNAs of essential genes that function to inhibit the essential genes. The present invention also provides neutralizing antibodies to proteins encoded by essential genes that bind to and inactivate the essential gene products. The present invention further provides pharmaceutical compositions for treating fungal and proliferative diseases, as well as methods of treatment of fungal and proliferative diseases.